Different downstream signalling of CCK1receptors regulates distinct functions of CCK in pancreatic beta cells
Open Access
- 23 October 2015
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 172 (21) , 5050-5067
Abstract
Background and Purpose: Cholecystokinin (CCK) is secreted by intestinal I cells and regulates important metabolic functions. In pancreatic islets, CCK controls beta cell functions primarily through CCK1receptors, but the signalling pathways downstream of these receptors in pancreatic beta cells are not well defined.Experimental Approach: Apoptosis in pancreatic beta cell apoptosis was evaluated using Hoechst‐33342 staining, TUNEL assays and Annexin‐V‐FITC/PI staining. Insulin secretion and second messenger production were monitored using ELISAs. Protein and phospho‐protein levels were determined by Western blotting. A glucose tolerance test was carried out to examine the functions of CCK‐8s in streptozotocin‐induced diabetic mice.Key Results: The sulfated carboxy‐terminal octapeptide CCK26‐33amide (CCK‐8s) activated CCK1receptors and induced accumulation of both IP3and cAMP. Whereas Gq‐PLC‐IP3signalling was required for the CCK‐8s‐induced insulin secretion under low‐glucose conditions, Gs‐PKA/Epac signalling contributed more strongly to the CCK‐8s‐mediated insulin secretion in high‐glucose conditions. CCK‐8s also promoted formation of the CCK1receptor/β‐arrestin‐1 complex in pancreatic beta cells. Using β‐arrestin‐1 knockout mice, we demonstrated that β‐arrestin‐1 is a key mediator of both CCK‐8s‐mediated insulin secretion and of its the protective effect against apoptosis in pancreatic beta cells. The anti‐apoptotic effects of β‐arrestin‐1 occurred through cytoplasmic late‐phase ERK activation, which activates the 90‐kDa ribosomal S6 kinase‐phospho–Bcl‐2‐family protein pathway.Conclusions and Implications: Knowledge of different CCK1receptor‐activated downstream signalling pathways in the regulation of distinct functions of pancreatic beta cells could be used to identify biased CCK1receptor ligands for the development of new anti‐diabetic drugs.Keywords
Funding Information
- National Natural Science Foundation of China (31271505)
- National Natural Science Foundation of China (31470789)
- National Natural Science Foundation of China (31270857)
This publication has 70 references indexed in Scilit:
- Structure of active β-arrestin-1 bound to a G-protein-coupled receptor phosphopeptideNature, 2013
- Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signalingTrends in Biochemical Sciences, 2011
- A Single Mutation in Arrestin-2 Prevents ERK1/2 Activation by Reducing c-Raf1 BindingBiochemistry, 2011
- Therapeutic potential of β-arrestin- and G protein-biased agonistsTrends in Molecular Medicine, 2011
- Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitusDiabetes Therapy, 2011
- Global phosphorylation analysis of β-arrestin–mediated signaling downstream of a seven transmembrane receptor (7TMR)Proceedings of the National Academy of Sciences, 2010
- Teaching old receptors new tricks: biasing seven-transmembrane receptorsNature Reviews Drug Discovery, 2010
- GLP-1 Mediates Antiapoptotic Effect by Phosphorylating Bad through a β-Arrestin 1-mediated ERK1/2 Activation in Pancreatic β-CellsJournal of Biological Chemistry, 2010
- The RSK family of kinases: emerging roles in cellular signallingNature Reviews Molecular Cell Biology, 2008
- β-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic β cellsProceedings of the National Academy of Sciences, 2008